Teva Wins U.S. Nod for Actavis After Divestiture of 79 Drugs

Updated on
  • FTC approves deal for Allergan’s generic drug-making unit
  • Agreement requires largest divestiture ever for pharma deal

The U.S. Federal Trade Commission approved Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generic drug-making unit after the companies agreed to the biggest divestiture ever in a pharmaceutical merger to preserve competition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.